SML3215
Remogliflozin etabonate
≥98% (HPLC)
别名:
5-Methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-?-D-glucopyranoside, BHV 091009, BHV-091009, GSK 189075, GSK-189075, GSK189075
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C26H38N2O9
化学文摘社编号:
分子量:
522.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -16 to -22°, c = 1 in DMSO
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[n]1(nc(c(c1C)Cc3ccc(cc3)OC(C)C)O[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)COC(=O)OCC)C(C)C
InChI
1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
InChI key
UAOCLDQAQNNEAX-ABMICEGHSA-N
Biochem/physiol Actions
Orally available prodrug of the potent and selective sodium glucose cotransporter SGLT2 (SLC5A2) inhibitor remogliflozin with antidiabetic efficacies in vivo.
Remogliflozin etabonate is an orally available prodrug form of the potent and selective low-affinity sodium glucose cotransporter SGLT2 (SLC5A2) inhibitor remogliflozin (human/rat SGLT2 Ki = 12.4/26.0 nM; human/rat SGLT1 Ki = 4.52/0.997 μM by AMG uptake assay using respective COS-7 transfectants) that prevents plasma glucose increase after glucose loading by increasing urinary glucose excretion in vivo (3-30 mg/kg mice and 1-10 mg/kg rats p.o.) without stimulating insulin secretion. Remogliflozin etabonate shows antidiabetic efficacies in animal models in vivo (1-10 mg/kg p.o.), including STZ-induced diabetic rats, db/db mice, and high-fat fed-GK rats (0.01-0.1% drug in HFD).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable